Herein, we aimed to evaluate the feasibility of targeted inhibition of TNF and IL1β expression in hepatic macrophages via exosomes as a potential therapeutic strategy for NASH. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatohepatitis.